Harbin Pharmaceutical Group Co Ltd (600664) - Total Liabilities
Based on the latest financial reports, Harbin Pharmaceutical Group Co Ltd (600664) has total liabilities worth CN¥7.67 Billion CNY (≈ $1.12 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 600664 cash flow conversion to assess how effectively this company generates cash.
Harbin Pharmaceutical Group Co Ltd - Total Liabilities Trend (1993–2024)
This chart illustrates how Harbin Pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Harbin Pharmaceutical Group Co Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
Harbin Pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Harbin Pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen Baoming Technology Co
SHE:002992
|
China | CN¥1.49 Billion |
|
Nanobiotix S.A
PA:NANO
|
France | €114.13 Million |
|
Jiangsu SOPO Chemical Co Ltd
SHG:600746
|
China | CN¥1.37 Billion |
|
Sichuan Crun Co Ltd
SHE:002272
|
China | CN¥2.13 Billion |
|
Beijing Cuiwei Tower Co Ltd
SHG:603123
|
China | CN¥4.65 Billion |
|
Kingenta Ecological Engineering Group Co Ltd
SHE:002470
|
China | CN¥9.57 Billion |
|
HeBei Jinniu Chemical Industry Co Ltd
SHG:600722
|
China | CN¥127.63 Million |
|
Jiangsu Jiuding New Material Co Ltd
SHE:002201
|
China | CN¥2.00 Billion |
Liability Composition Analysis (1993–2024)
This chart breaks down Harbin Pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 600664 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.44 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Harbin Pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Harbin Pharmaceutical Group Co Ltd (1993–2024)
The table below shows the annual total liabilities of Harbin Pharmaceutical Group Co Ltd from 1993 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥8.53 Billion ≈ $1.25 Billion |
-1.87% |
| 2023-12-31 | CN¥8.69 Billion ≈ $1.27 Billion |
+2.41% |
| 2022-12-31 | CN¥8.48 Billion ≈ $1.24 Billion |
+0.75% |
| 2021-12-31 | CN¥8.42 Billion ≈ $1.23 Billion |
+7.16% |
| 2020-12-31 | CN¥7.86 Billion ≈ $1.15 Billion |
+19.81% |
| 2019-12-31 | CN¥6.56 Billion ≈ $959.89 Million |
+16.72% |
| 2018-12-31 | CN¥5.62 Billion ≈ $822.38 Million |
-9.61% |
| 2017-12-31 | CN¥6.22 Billion ≈ $909.85 Million |
-7.95% |
| 2016-12-31 | CN¥6.75 Billion ≈ $988.42 Million |
+7.51% |
| 2015-12-31 | CN¥6.28 Billion ≈ $919.40 Million |
-15.92% |
| 2014-12-31 | CN¥7.47 Billion ≈ $1.09 Billion |
-2.72% |
| 2013-12-31 | CN¥7.68 Billion ≈ $1.12 Billion |
+9.51% |
| 2012-12-31 | CN¥7.02 Billion ≈ $1.03 Billion |
+33.73% |
| 2011-12-31 | CN¥5.25 Billion ≈ $767.63 Million |
+0.55% |
| 2010-12-31 | CN¥5.22 Billion ≈ $763.43 Million |
+29.69% |
| 2009-12-31 | CN¥4.02 Billion ≈ $588.68 Million |
+3.30% |
| 2008-12-31 | CN¥3.89 Billion ≈ $569.86 Million |
-11.41% |
| 2007-12-31 | CN¥4.40 Billion ≈ $643.22 Million |
-0.81% |
| 2006-12-31 | CN¥4.43 Billion ≈ $648.45 Million |
+4.56% |
| 2005-12-31 | CN¥4.24 Billion ≈ $620.15 Million |
+18.16% |
| 2004-12-31 | CN¥3.59 Billion ≈ $524.83 Million |
+4.00% |
| 2003-12-31 | CN¥3.45 Billion ≈ $504.63 Million |
+12.14% |
| 2002-12-31 | CN¥3.08 Billion ≈ $450.00 Million |
-0.43% |
| 2001-12-31 | CN¥3.09 Billion ≈ $451.94 Million |
+9.36% |
| 2000-12-31 | CN¥2.82 Billion ≈ $413.25 Million |
-3.90% |
| 1999-12-31 | CN¥2.94 Billion ≈ $430.00 Million |
+25.37% |
| 1998-12-31 | CN¥2.34 Billion ≈ $342.99 Million |
+31.45% |
| 1997-12-31 | CN¥1.78 Billion ≈ $260.94 Million |
+4.94% |
| 1996-12-31 | CN¥1.70 Billion ≈ $248.65 Million |
-1.56% |
| 1995-12-31 | CN¥1.73 Billion ≈ $252.58 Million |
+0.98% |
| 1994-12-31 | CN¥1.71 Billion ≈ $250.12 Million |
+4.14% |
| 1993-12-31 | CN¥1.64 Billion ≈ $240.18 Million |
-- |
About Harbin Pharmaceutical Group Co Ltd
Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, anti-virus and anti-infection, cere… Read more